Oct 17 (Reuters) - Medical device maker Boston Scientific ( BSX ) said on Friday it will

buy the remaining equity in privately held Nalu Medical for about $533 million in cash,

expanding its treatments for chronic pain.

The deal gives Boston Scientific ( BSX ) access to Nalu's Neurostimulation System, which is

designed to deliver targeted relief for adults living with chronic pain in areas such as the

shoulder, lower back and knee, through peripheral nerve stimulation.

The therapy uses mild electrical impulses to interrupt pain signals before they reach

the brain and features a miniaturized, battery-free implantable pulse generator, powered

wirelessly by a small, externally worn therapy disc and controlled via a smartphone app.

Boston Scientific ( BSX ) has been a strategic investor in Nalu Medical since 2017. The

transaction is expected to complete in the first half of 2026.